MEDIA KIT
Kent Imaging Announces FDA CLEARANCE of SnapshotNIR (KD205)
Kent Imaging announces the latest model of SnapshotNIR that expands the use of the technology to include more skin tones, advancing tissue assessment.
CONTACT KENT IMAGING PRESS AND MEDIA:
marketing@kentimaging.com
Changing the way clinicians treat acute and chronic wounds with actionable Tissue insights they never had before
The innovative SNAPSHOTNIR
SnapshotNIR uses near-infrared wavelengths of light to measure tissue oxygen saturation (StO2) and is the only device on the market to monitor hemoglobin trends in microcirculation.
SnapshotNIR captures the data in <2s so physicians can view the patient’s status at the bedside improving patient education, compliance and rapport. The camera-like device takes pictures depicting a colorful StO2 image that can be used in medical decision-making, for tracking and monitoring healing trends, and evaluating tissue viability and blood flow in wound care, vascular and surgical applications.
WHY IS SNAPSHOTNIR IMPORTANT?
Understanding the capacity of a wound to heal is essential across health fields including chronic wounds, surgical cases and vascular diseases.
14-24% of patients with diabetes mellitus will develop a diabetic foot ulcer during their lifetime and up to 1 in 4 of those patients will undergo an amputation - that’s an amputation every 30 seconds annually (1, 2).
There is a 46% risk of death within the first 5 years after a minor amputation and 57% risk after a major amputation (3).
In reconstructive surgery, 1 in 3 mastectomies result in post-operative complications over the next two years and almost 20% of patients will require further surgery (4).
Current diagnostic tools to assess tissue health are either costly or difficult to employ and visual assessment alone is not adequate to see the whole picture.
Snapshot’s proprietary algorithm has automatic calibration for melanated skin and can be used to measure tissue oxygenation saturation anywhere on the body.
In vascular disease assessments like Peripheral Arterial Disease and Chronic Limb-Threatening Ischemia, ‘gold standard’ diagnostics, ABIs, will miss the diagnosis up to 60% of the time (5).
SnapshotNIR documentation reports can be used to support medical necessity of interventions and proof of therapeutic efficacy for hospital systems.
There is minimal training required so doctors, nurses and care providers can implement the technology in their systems immediately.
what makes snapshotnir different?
an algorithm for positive change
Advancing healthcare
Kent’s proprietary algorithm expands the technology use to include patients with high melanin content. PRESS RELEASE
Intra-operative surgery
Snapshot can predict skin flap necrosis during post-mastectomy breast reconstructions reducing complication rates and improving patient quality of life. PUBLICATION
Chronic wound treatment
Oxygen is the number one requirement for tissue healing. Track tissue oxygenation using Snapshot to direct interventions. Faster wound closure than the national average is possible. CASE STUDY
Reduce physician burden
Doctors need more time with patients and less time in paperwork. Quick, accurate, repeatable objective data and ease-of-use allows physicians to take control of their time without compromising on patient care. REIMBURSEMENT
Microvascular assessment
Snapshot shows the small blood vessels that are impacted most in diabetes and peripheral arterial disease assessing trends in oxy- and deoxy-hemoglobin. Screen patients and expedite referrals for vascular surgery. PUBLICATION
Customer success with SnapshotNIR
“With SnapshotNIR, I can take a picture and get a result within mere seconds.”
Dr. Misael Alonso, MD
“Snapshot gives us a better idea of what’s actually happening in the wound, underneath the skin.”
Dr. Naz Wahab, MD
“SnapshotNIR lets us look below the skin’s surface, beyond what we can see with the naked eye. It changes the game.”
Martha Kelso, Wound Care Plus
Near the start of the millennium, the National Research Council of Canada had completed a lab model to show proof of concept of near-infrared spectroscopy (NIRS) to look at human tissue for the concentration of oxygen. Kent’s Founder and Executive Chairman, Don Chapman, was intrigued by its potential in the medical setting and Kent Imaging was formed.
Initial funding from the founder and several private investors, coupled with stringent cost controls, allowed the organization to move through several years and iterations of design and field-testing programs until a smaller, sleeker, handheld unit was devised.
WHo we are
LEADERSHIP TEAM
Don Chapman Founder & Executive Chairman
Pierre Lemire CEO
Daryl Reed VP, Global Sales
Sandra Jenks VP, Global Marketing
Chamith Rathnayake VP, Manufacturing Operations
Christine Shettel VP, Clinical Services
Jason Nessler VP, Product Development
Dr. Jeffrey Niezgoda CMO, Limb Preservation
Dr. Glyn Jones CMO, Surgery
COMPANY MILESTONES
2015 Pierre Lemire was welcomed to the team as an experienced CEO to lead the development of medical technology solutions and manage the company’s expansion into the future.
2017 The FDA cleared Snapshot V2.0 (KD203), the next iteration of the NIR imaging device, featuring a battery-powered handheld footprint with no docking station or wires.
2022 Snapshot V4.0 (KD204T) was released with advanced wound measurement functions as well as a customizable reporting feature. PRESS RELEASE
2022 Kent Imaging appointed two specialized CMO’s for Limb Preservation and Surgery. PRESS RELEASE
2023 the company expanded its sales to new international markets including Australia, Israel, and Egypt.
Summer 2023 Kent Imaging moved its Calgary-based headquarters to a larger office and production space. PRESS RELEASE
April 2024 Announces a pivotal advancement to SnapshotNIR (KD205) with an algorithm update that optimizes NIRS imaging for all areas of the body, in nearly all skin tones, effectively addressing the melanin barrier in medical imaging. PRESS RELEASE
ground-breaking innovation is hard to ignore
Global News GameChangers feature
Click on a feature to read
in the hands of clinicians worldwide
PRESS AND MEDIA CONTACT:
marketing@kentimaging.com
References: (1) Sen CK. Human wound and its burden: updated 2022 compendium of estimates. Advances in wound care. 2023 Dec 1;12(12):657-70. (2) Dayya D, O'Neill OJ, Huedo-Medina TB, Habib N, Moore J, Iyer K. Debridement of diabetic foot ulcers. Advances in wound care. 2022 Dec 1;11(12):666-86. (3) Armstrong DG, Swerdlow MA, Armstrong AA, Conte MS, Padula WV, Bus SA. Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. Journal of foot and ankle research. 2020 Dec;13:1-4. (4) Bennett KG, Qi J, Kim HM, Hamill JB, Pusic AL, Wilkins EG. Comparison of 2-Year Complication Rates Among Common Techniques for Postmastectomy Breast Reconstruction. JAMA Surg. 2018;153(10):901–908. doi:10.1001/jamasurg.2018.1687. (5) AbuRahma AF, Adams E, AbuRahma J, Mata LA, Dean LS, Caron C, Sloan J. Critical analysis and limitations of resting ankle-brachial index in the diagnosis of symptomatic peripheral arterial disease patients and the role of diabetes mellitus and chronic kidney disease. Journal of vascular surgery. 2020 Mar 1;71(3):937-45.